Jane Street Group LLC Has $15.27 Million Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Jane Street Group LLC lessened its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 34.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 192,189 shares of the company's stock after selling 99,620 shares during the quarter. Jane Street Group LLC's holdings in Dr. Reddy's Laboratories were worth $15,269,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its stake in shares of Dr. Reddy's Laboratories by 3.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,995,495 shares of the company's stock valued at $152,037,000 after purchasing an additional 65,606 shares during the period. Dimensional Fund Advisors LP lifted its stake in Dr. Reddy's Laboratories by 12.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company's stock valued at $76,455,000 after buying an additional 114,294 shares during the period. State Street Corp raised its position in shares of Dr. Reddy's Laboratories by 1.9% in the 3rd quarter. State Street Corp now owns 909,905 shares of the company's stock valued at $72,292,000 after acquiring an additional 16,641 shares during the period. Fisher Asset Management LLC boosted its stake in Dr. Reddy's Laboratories by 59.4% during the 3rd quarter. Fisher Asset Management LLC now owns 491,303 shares of the company's stock worth $39,034,000 after acquiring an additional 183,146 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Dr. Reddy's Laboratories by 30.8% during the third quarter. BNP Paribas Financial Markets now owns 409,440 shares of the company's stock worth $32,530,000 after purchasing an additional 96,339 shares in the last quarter. Institutional investors own 3.85% of the company's stock.

Wall Street Analyst Weigh In

RDY has been the subject of a number of research analyst reports. StockNews.com cut Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, December 6th. Barclays cut their price objective on shares of Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 6th.

Dr. Reddy's Laboratories Stock Up 0.6 %

Dr. Reddy's Laboratories stock traded up $0.09 during midday trading on Friday, reaching $14.49. The stock had a trading volume of 651,012 shares, compared to its average volume of 1,065,261. The stock has a market capitalization of $12.09 billion, a P/E ratio of 23.01 and a beta of 0.53. The firm's fifty day simple moving average is $14.90 and its 200-day simple moving average is $15.36. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.36 and a current ratio of 1.92. Dr. Reddy's Laboratories Limited has a 1-year low of $13.26 and a 1-year high of $16.89.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.